Welcome to our dedicated page for Sagimet Biosciences news (Ticker: SGMT), a resource for investors and traders seeking the latest updates and insights on Sagimet Biosciences stock.
Sagimet Biosciences Inc. (Nasdaq: SGMT) is a clinical-stage biopharmaceutical company committed to discovering and developing novel therapeutics targeting dysfunctional metabolic pathways. The company's lead drug candidate, denifanstat, is an innovative, oral, once-daily pill that selectively inhibits fatty acid synthase (FASN). This inhibitor is specifically designed for the treatment of nonalcoholic steatohepatitis (NASH), a severe and progressive liver disease.
Denifanstat has recently achieved significant milestones. The FASCINATE-2 Phase 2b clinical trial demonstrated statistically significant improvements in primary and multiple secondary endpoints at week 52 in 168 NASH patients with stage 2 or 3 fibrosis. The results showed that denifanstat was generally well-tolerated, with the majority of adverse events being mild to moderate. Importantly, no treatment-related serious adverse events were observed.
Under an exclusive license agreement, Gannex Pharma Co., Ltd., a wholly-owned subsidiary of Ascletis Pharma Inc., holds the rights to develop, manufacture, and commercialize denifanstat (referred to as ASC40) in Greater China.
Founded in 2019, Gannex focuses on the R&D and commercialization of novel drugs for NASH, with three clinical stage candidates targeting different pathways—FASN, THRβ, and FXR. Ascletis Pharma Inc., listed on the Hong Kong Stock Exchange, leads the global effort in viral diseases, NASH, and oncology, with several advanced drug candidates in its pipeline.
Sagimet's commitment to addressing unmet medical needs in metabolic dysfunction has placed it at the forefront of NASH treatment innovation. The company's current projects and partnerships highlight its potential for significant impact in the biopharmaceutical industry.
Sagimet Biosciences Inc. announced the oral presentation of denifanstat Phase 2b FASCINATE-2 study data at the EASL International Liver Congress 2024. The study demonstrated significant fibrosis improvement and MASH resolution in patients with F2 or F3 fibrosis.
Sagimet Biosciences Inc. announced the appointment of Thierry Chauche as Chief Financial Officer. Chauche brings over 20 years of financial and biopharma experience to the role. The company granted him an inducement stock option worth $2 million. Additionally, Sagimet approved inducement grants of stock options for four other newly-hired employees.
FAQ
What is the current stock price of Sagimet Biosciences (SGMT)?
What is the market cap of Sagimet Biosciences (SGMT)?
What is Sagimet Biosciences Inc.?
What is denifanstat?
What were the results of the FASCINATE-2 Phase 2b clinical trial?
Who holds the rights to denifanstat in Greater China?
What is NASH?
How does denifanstat work?
What other projects is Sagimet Biosciences working on?
What is the significance of the partnership with Gannex Pharma?
What are the company's future plans?
Where can I find more information about Sagimet Biosciences?
